ANZCTR search results

The study is an open study examining the effects of withdrawal of oral iron supplements in patients with the genetic condition Cystic Fibrosis (CF). In CF it is believed that unusually high levels of iron can be found in respiratory tract, and that the presence of iron within the airways may promote bacterial infection. In this study we explore how withdrawal of iron supplements may effect airway iron content and microbiology. As well as assessing the effect on systemic iron stores, lung function, and disease related symptoms. This study will be conducted by the staff of the Adult Cystic Fibrosis Centre located at The Prince Charles Hospital, Brisbane, Australia. All patients who meet the inclusion criteria will be invited to participate. Subjects will provide written informed consent prior to participation. If patients decide to withdraw from the study at any point this will not have any impact on their ongoing care.

this trial will investigate the effect of preservatives in comfort eye-drops on corneal epithelial cells

This project aims to test whether a new blood glucose monitoring system increases the number of tests that patients with type 1 diabetes do as compared with an existing blood glucose monitoring system. The project also aims to test whether the new blood glucose testing system improves diabetic control and improves how you feel about your diabetes. The project also aims to test whether the new blood glucose testing system is preferred by users over the existing system Many studies have demonstrated that regular self monitoring of blood glucose improved overall control in type 1 diabetes and that better control results in better long-term outcomes and fewer complications. There are many reasons why people with type 1 diabetes do not monitor optimally. These include forgetfulness, difficulties with handling and disposing of test strips, lifestyle alignment (embarrassment of monitoring in public and lack of time and difficulty monitoring away from home), as well as inability to make decisions based on results. The new blood glucose testing system addresses some of these issues and previous surveys have shown that compliance with a testing regime is improved. There has, however, not been a formal study of the system to date and this study hopes to fill that gap in medical knowledge. Fifty people with type 1 diabetes will be recruited from Eastern Health and Royal Prince Alfred diabetes clinics to participate in the study. Subjects will be randomized to receive either the existing or the new system to begin with and to use that system for 3 months. After that period subjects will swap to the alternate system for a further 3 months. At the end of 6 months subject will be able to chose which system they prefer to use for the remaining 3 months of the study which therefore has a total duration of 9 months. Subjects will be required to attend every 3 months during the study (total of 4 visits) at which time the content of the meters memory will be down loaded for analysis. Subject will also be asked to complete questionnaires relating to their mood, level of distress, attitude and satisfaction.

Aim: To determine the most effective way of detecting the incidence of allergic conjunctivitis (AC). Method: The first step includes asking patients in an allergy specialist's outpatient clinic about their Total Ocular Symptom Score (tearing, itching and eye redness), then asking them about indirect symptoms of AC (squinting, blinking, frontal headaches or eyelid dermatitis), and finally using an olopatadine challenge to determine if any chronic, undetected symptoms of AC are relieved and thus suffered. A control group will be used to determine if the lubricating effects of the olopatadine eye drops is acting as the relieving factor in the intervention group.

Burn injuries result in pain, inflammation and destruction of skin cells. Skin grafting will be required when the depth of the injury destroys the deeper skin layers. Despite grafting, the burn injury continues to produce inflammatory chemicals or mediators. These mediators result in a thickened and raised scar with increased sensitivity and itching. The purpose of this research is to see if Clobetasol propionate can reduce the inflammatory mediators thereby reducing active scar tissue formation.

A significant amount of research demonstrates that CBT is effective in reducing anxiety in youngsters aged 7 to 17 years using both face-to-face and online formats. Surprisingly, however, little research has investigated the efficacy of early intervention for anxiety disorders in the preschool years. Over the last several years, our research team has been systematically developing an internet-based CBT program for the treatment of childhood anxiety disorders. This pilot study intends to investigate the potential efficacy of an online CBT intervention delivered to the parents of anxious 3-5 year old children.

The primary aim of this study is to compare the effects of two approaches to the administration of beta-lactam antibiotics (continuous infusion and intermittent bolus dosing) on ICU-free days up to Day 28, with dosing at clinician discretion and independent of randomisation group. The null hypothesis is that there is no difference in ICU-free days up to Day 28 between patients assigned to continuous infusion and those assigned to standard bolus dosing.

This study will evaluate whether giving standard chemotherapy treatment more quickly can be done safely and will be more effective in treating patients with Hodgkin Lymphoma. Who is it for? You may be eligible to join this study if you are aged between 16-60 years and have been diagnosed with either early stage unfavourable or advanced stage Hodgkin Lymphoma. Trial details The current standard therapy for Hodgkin Lymphoma involves receiving a four drug chemotherapy regimen called 'ABVD' every fourteen days. ABVD is an abbreviation for the four drugs used (A=adriamycin, B=bleomycin, V=vinblastin, D=dacarbazine). This chemotherapy is generally well tolerated. A full cycle of therapy involves ABVD given on days 1 and 15 of a 28 day (=4 week) cycle. In this trial, all participants! will receive the exact same four drug combination (ABVD) but given on days 1 and 12 of a 21 day (=3 week) cycle. A growth factor called Nivestim will be given to accelerate the recovery of the body's normal blood cells from the effects of ABVD and thus allow the chemotherapy to be given more quickly than usual. Participants will undergo between 4 to 8 cycles of treatment depending on response. Participants will be regularly assessed over a period of up to 5 years to determine the safety and efficacy of this accelerated chemotherapy regime.

This study aims to investigate whether the combination of everolimus (RAD001), fluvastatin, and zoledronic acid can be given safely together and to determine the toxicities, if any, of the combination. Who is it for? You may be eligible for this study if you have advanced cancer which has continued to grow despite the use of other therapies. Trial Details In this trial, you will receive an combined treatment of the drugs Everolimus escalating from 2.5mg to 10mg daily, fluvastatin 80mg to 120mg daily, and zoledronic acid 4mg intravenously every 3 weeks until either you experience intolerable side effects or until your cancer grows again. We hope that the combination treatment will ultimately not only be fairly well tolerated, but act synergistically to help slow down the rate of tumour growth.

The purpose of this research study is to investigate whether a treatment involving the delivery of protein supplements into the vein (intravenous) can protect cardiac bypass surgery patients from the onset of a new kidney injury, when compared with standard treatment.